FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959432976> ?p ?o ?g. }

• W2959432976 endingPage "3534" @default.
• W2959432976 startingPage "3526" @default.
• W2959432976 abstract "The IMpower150 trial found that adding atezolizumab to the combination of bevacizumab and chemotherapy improved survival for patients with metastatic, nonsquamous non-small cell lung cancer (NSCLC). However, considering the high cost of immunotherapy, there is a need to assess its value by considering both efficacy and cost. The current study evaluated the cost-effectiveness of atezolizumab in the first-line setting for the treatment of patients with metastatic NSCLC from the US payer perspective.A Markov model was developed to compare the lifetime cost and effectiveness of the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) with the combination of bevacizumab, carboplatin, and paclitaxel (BCP) and carboplatin and paclitaxel (CP) in the first-line treatment of patients with metastatic NSCLC. Life-years (LYs), quality-adjusted LYs (QALYs), and lifetime costs were estimated. One-way and probabilistic sensitivity analyses were performed to evaluate the model uncertainty. Additional subgroup analyses were performed.ABCP provided an additional 0.413 QALYs (0.460 LYs) and 0.738 QALYs (0.956 LYs), respectively, compared with BCP and CP. The corresponding incremental costs were $234,998 and $381,116, respectively. The incremental cost-effectiveness ratio for ABCP was $568,967 per QALY compared with BCP and $516,114 per QALY compared with CP. The subgroup analysis demonstrated that PD-L1 expression of ≥50% on tumor cells (TC3) or ≥10% on immune cells (IC3) decreased the incremental cost-effectiveness ratio to $464,703 per QALY.From the perspective of the US payer, ABCP is estimated to not be cost-effective compared with BCP or CP in the first-line setting for patients with metastatic, nonsquamous NSCLC at a willingness-to-pay threshold of $100,000 per QALY." @default.
• W2959432976 created "2019-07-23" @default.
• W2959432976 creator A5015533842 @default.
• W2959432976 creator A5023174618 @default.
• W2959432976 creator A5035411778 @default.
• W2959432976 creator A5057587462 @default.
• W2959432976 creator A5062959247 @default.
• W2959432976 creator A5067812233 @default.
• W2959432976 date "2019-07-09" @default.
• W2959432976 modified "2023-10-15" @default.
• W2959432976 title "First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis" @default.
• W2959432976 cites W1982967337 @default.
• W2959432976 cites W1998034034 @default.
• W2959432976 cites W2001247327 @default.
• W2959432976 cites W2058056848 @default.
• W2959432976 cites W2070487839 @default.
• W2959432976 cites W2120120139 @default.
• W2959432976 cites W2120676861 @default.
• W2959432976 cites W2128473443 @default.
• W2959432976 cites W2130320283 @default.
• W2959432976 cites W2133075384 @default.
• W2959432976 cites W2145835533 @default.
• W2959432976 cites W2152897456 @default.
• W2959432976 cites W2181792533 @default.
• W2959432976 cites W2263279668 @default.
• W2959432976 cites W2296800272 @default.
• W2959432976 cites W2519603001 @default.
• W2959432976 cites W2542029846 @default.
• W2959432976 cites W2567564314 @default.
• W2959432976 cites W2625574648 @default.
• W2959432976 cites W2625652544 @default.
• W2959432976 cites W2735117693 @default.
• W2959432976 cites W2749428689 @default.
• W2959432976 cites W2769988386 @default.
• W2959432976 cites W2781525129 @default.
• W2959432976 cites W2782646756 @default.
• W2959432976 cites W2788271038 @default.
• W2959432976 cites W2788385232 @default.
• W2959432976 cites W2798010797 @default.
• W2959432976 cites W2805354595 @default.
• W2959432976 cites W2888716743 @default.
• W2959432976 cites W2890318130 @default.
• W2959432976 doi "https://doi.org/10.1002/cncr.32368" @default.
• W2959432976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31287562" @default.
• W2959432976 hasPublicationYear "2019" @default.
• W2959432976 type Work @default.
• W2959432976 sameAs 2959432976 @default.
• W2959432976 citedByCount "68" @default.
• W2959432976 countsByYear W29594329762019 @default.
• W2959432976 countsByYear W29594329762020 @default.
• W2959432976 countsByYear W29594329762021 @default.
• W2959432976 countsByYear W29594329762022 @default.
• W2959432976 countsByYear W29594329762023 @default.
• W2959432976 crossrefType "journal-article" @default.
• W2959432976 hasAuthorship W2959432976A5015533842 @default.
• W2959432976 hasAuthorship W2959432976A5023174618 @default.
• W2959432976 hasAuthorship W2959432976A5035411778 @default.
• W2959432976 hasAuthorship W2959432976A5057587462 @default.
• W2959432976 hasAuthorship W2959432976A5062959247 @default.
• W2959432976 hasAuthorship W2959432976A5067812233 @default.
• W2959432976 hasBestOaLocation W29594329761 @default.
• W2959432976 hasConcept C112930515 @default.
• W2959432976 hasConcept C121608353 @default.
• W2959432976 hasConcept C126322002 @default.
• W2959432976 hasConcept C143998085 @default.
• W2959432976 hasConcept C2775949291 @default.
• W2959432976 hasConcept C2776256026 @default.
• W2959432976 hasConcept C2776694085 @default.
• W2959432976 hasConcept C2777292972 @default.
• W2959432976 hasConcept C2777701055 @default.
• W2959432976 hasConcept C2777802072 @default.
• W2959432976 hasConcept C2778239845 @default.
• W2959432976 hasConcept C2780057760 @default.
• W2959432976 hasConcept C2781451048 @default.
• W2959432976 hasConcept C3019080777 @default.
• W2959432976 hasConcept C71924100 @default.
• W2959432976 hasConceptScore W2959432976C112930515 @default.
• W2959432976 hasConceptScore W2959432976C121608353 @default.
• W2959432976 hasConceptScore W2959432976C126322002 @default.
• W2959432976 hasConceptScore W2959432976C143998085 @default.
• W2959432976 hasConceptScore W2959432976C2775949291 @default.
• W2959432976 hasConceptScore W2959432976C2776256026 @default.
• W2959432976 hasConceptScore W2959432976C2776694085 @default.
• W2959432976 hasConceptScore W2959432976C2777292972 @default.
• W2959432976 hasConceptScore W2959432976C2777701055 @default.
• W2959432976 hasConceptScore W2959432976C2777802072 @default.
• W2959432976 hasConceptScore W2959432976C2778239845 @default.
• W2959432976 hasConceptScore W2959432976C2780057760 @default.
• W2959432976 hasConceptScore W2959432976C2781451048 @default.
• W2959432976 hasConceptScore W2959432976C3019080777 @default.
• W2959432976 hasConceptScore W2959432976C71924100 @default.
• W2959432976 hasFunder F4320321001 @default.
• W2959432976 hasIssue "20" @default.
• W2959432976 hasLocation W29594329761 @default.
• W2959432976 hasLocation W29594329762 @default.
• W2959432976 hasOpenAccess W2959432976 @default.
• W2959432976 hasPrimaryLocation W29594329761 @default.
• W2959432976 hasRelatedWork W1502181122 @default.

• next